Cargando…
Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment
Purpose: To assess the utility of measurement of the computed tomography (CT) attenuation value (CTav) in predicting tumor necrosis in hepatocellular carcinoma (HCC) patients who achieve a complete response (CR), defined using modified Response Evaluation Criteria in Solid Tumors (mRECIST), after le...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139739/ https://www.ncbi.nlm.nih.gov/pubmed/35621656 http://dx.doi.org/10.3390/curroncol29050266 |
_version_ | 1784714928692658176 |
---|---|
author | Chuma, Makoto Yokoo, Hideki Hiraoka, Atsushi Ueda, Kazuhiko Yokoyama, Takahiro Tsuji, Kunihiko Shimada, Noritomo Uojima, Haruki Kobayashi, Satoshi Hattori, Nobuhiro Okubo, Tomomi Atsukawa, Masanori Ishikawa, Toru Takaguchi, Koichi Tsutsui, Akemi Toyoda, Hidenori Tada, Toshifumi Saito, Yoshinori Hirose, Shunji Tanaka, Takaaki Takeda, Kazuhisa Otani, Masako Sekikawa, Zenjiro Watanabe, Tsunamasa Hidaka, Hisashi Morimoto, Manabu Numata, Kazushi Kagawa, Tatehiro Sakamoto, Michiie Kumada, Takashi Maeda, Shin |
author_facet | Chuma, Makoto Yokoo, Hideki Hiraoka, Atsushi Ueda, Kazuhiko Yokoyama, Takahiro Tsuji, Kunihiko Shimada, Noritomo Uojima, Haruki Kobayashi, Satoshi Hattori, Nobuhiro Okubo, Tomomi Atsukawa, Masanori Ishikawa, Toru Takaguchi, Koichi Tsutsui, Akemi Toyoda, Hidenori Tada, Toshifumi Saito, Yoshinori Hirose, Shunji Tanaka, Takaaki Takeda, Kazuhisa Otani, Masako Sekikawa, Zenjiro Watanabe, Tsunamasa Hidaka, Hisashi Morimoto, Manabu Numata, Kazushi Kagawa, Tatehiro Sakamoto, Michiie Kumada, Takashi Maeda, Shin |
author_sort | Chuma, Makoto |
collection | PubMed |
description | Purpose: To assess the utility of measurement of the computed tomography (CT) attenuation value (CTav) in predicting tumor necrosis in hepatocellular carcinoma (HCC) patients who achieve a complete response (CR), defined using modified Response Evaluation Criteria in Solid Tumors (mRECIST), after lenvatinib treatment. Method: We compared CTav in arterial phase CT images with postoperative histopathology in four patients who underwent HCC resection after lenvatinib treatment, to determine CTav thresholds indicative of histological necrosis (N-CTav). Next, we confirmed the accuracy of the determined N-CTav in 15 cases with histopathologically proven necrosis in surgical specimens. Furthermore, the percentage of the tumor with N-CTav, i.e., the N-CTav occupancy rate, assessed using Image J software in 30 tumors in 12 patients with CR out of 571 HCC patients treated with lenvatinib, and its correlation with local recurrence following CR were examined. Results: Receiver operating characteristic (ROC) curve analysis revealed an optimal cut-off value of CTav of 30.2 HU, with 90.0% specificity and 65.0% sensitivity in discriminating between pathologically identified necrosis and degeneration, with a CTav of less than 30.2 HU indicating necrosis after lenvatinib treatment (N30-CTav). Furthermore, the optimal cut-off value of 30.6% for the N30-CTav occupancy rate by ROC analysis was a significant indicator of local recurrence following CR with 76.9% specificity and sensitivity (area under the ROC curve; 0.939), with the CR group with high N30-CTav occupancy (≥30.6%) after lenvatinib treatment showing significantly lower local recurrence (8.3% at 1 year) compared with the low (<30.6%) N30-CTav group (p < 0.001, 61.5% at 1 year). Conclusion: The cut-off value of 30.2 HU for CTav (N30-CTav) might be appropriate for identifying post-lenvatinib necrosis in HCC, and an N30-CTav occupancy rate of >30.6% might be a predictor of maintenance of CR. Use of these indicators have the potential to impact systemic chemotherapy for HCC. |
format | Online Article Text |
id | pubmed-9139739 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91397392022-05-28 Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment Chuma, Makoto Yokoo, Hideki Hiraoka, Atsushi Ueda, Kazuhiko Yokoyama, Takahiro Tsuji, Kunihiko Shimada, Noritomo Uojima, Haruki Kobayashi, Satoshi Hattori, Nobuhiro Okubo, Tomomi Atsukawa, Masanori Ishikawa, Toru Takaguchi, Koichi Tsutsui, Akemi Toyoda, Hidenori Tada, Toshifumi Saito, Yoshinori Hirose, Shunji Tanaka, Takaaki Takeda, Kazuhisa Otani, Masako Sekikawa, Zenjiro Watanabe, Tsunamasa Hidaka, Hisashi Morimoto, Manabu Numata, Kazushi Kagawa, Tatehiro Sakamoto, Michiie Kumada, Takashi Maeda, Shin Curr Oncol Article Purpose: To assess the utility of measurement of the computed tomography (CT) attenuation value (CTav) in predicting tumor necrosis in hepatocellular carcinoma (HCC) patients who achieve a complete response (CR), defined using modified Response Evaluation Criteria in Solid Tumors (mRECIST), after lenvatinib treatment. Method: We compared CTav in arterial phase CT images with postoperative histopathology in four patients who underwent HCC resection after lenvatinib treatment, to determine CTav thresholds indicative of histological necrosis (N-CTav). Next, we confirmed the accuracy of the determined N-CTav in 15 cases with histopathologically proven necrosis in surgical specimens. Furthermore, the percentage of the tumor with N-CTav, i.e., the N-CTav occupancy rate, assessed using Image J software in 30 tumors in 12 patients with CR out of 571 HCC patients treated with lenvatinib, and its correlation with local recurrence following CR were examined. Results: Receiver operating characteristic (ROC) curve analysis revealed an optimal cut-off value of CTav of 30.2 HU, with 90.0% specificity and 65.0% sensitivity in discriminating between pathologically identified necrosis and degeneration, with a CTav of less than 30.2 HU indicating necrosis after lenvatinib treatment (N30-CTav). Furthermore, the optimal cut-off value of 30.6% for the N30-CTav occupancy rate by ROC analysis was a significant indicator of local recurrence following CR with 76.9% specificity and sensitivity (area under the ROC curve; 0.939), with the CR group with high N30-CTav occupancy (≥30.6%) after lenvatinib treatment showing significantly lower local recurrence (8.3% at 1 year) compared with the low (<30.6%) N30-CTav group (p < 0.001, 61.5% at 1 year). Conclusion: The cut-off value of 30.2 HU for CTav (N30-CTav) might be appropriate for identifying post-lenvatinib necrosis in HCC, and an N30-CTav occupancy rate of >30.6% might be a predictor of maintenance of CR. Use of these indicators have the potential to impact systemic chemotherapy for HCC. MDPI 2022-05-04 /pmc/articles/PMC9139739/ /pubmed/35621656 http://dx.doi.org/10.3390/curroncol29050266 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chuma, Makoto Yokoo, Hideki Hiraoka, Atsushi Ueda, Kazuhiko Yokoyama, Takahiro Tsuji, Kunihiko Shimada, Noritomo Uojima, Haruki Kobayashi, Satoshi Hattori, Nobuhiro Okubo, Tomomi Atsukawa, Masanori Ishikawa, Toru Takaguchi, Koichi Tsutsui, Akemi Toyoda, Hidenori Tada, Toshifumi Saito, Yoshinori Hirose, Shunji Tanaka, Takaaki Takeda, Kazuhisa Otani, Masako Sekikawa, Zenjiro Watanabe, Tsunamasa Hidaka, Hisashi Morimoto, Manabu Numata, Kazushi Kagawa, Tatehiro Sakamoto, Michiie Kumada, Takashi Maeda, Shin Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment |
title | Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment |
title_full | Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment |
title_fullStr | Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment |
title_full_unstemmed | Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment |
title_short | Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment |
title_sort | identification of ct values that could be predictive of necrosis (n-ctav) in hepatocellular carcinoma after lenvatinib treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139739/ https://www.ncbi.nlm.nih.gov/pubmed/35621656 http://dx.doi.org/10.3390/curroncol29050266 |
work_keys_str_mv | AT chumamakoto identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT yokoohideki identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT hiraokaatsushi identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT uedakazuhiko identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT yokoyamatakahiro identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT tsujikunihiko identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT shimadanoritomo identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT uojimaharuki identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT kobayashisatoshi identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT hattorinobuhiro identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT okubotomomi identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT atsukawamasanori identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT ishikawatoru identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT takaguchikoichi identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT tsutsuiakemi identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT toyodahidenori identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT tadatoshifumi identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT saitoyoshinori identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT hiroseshunji identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT tanakatakaaki identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT takedakazuhisa identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT otanimasako identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT sekikawazenjiro identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT watanabetsunamasa identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT hidakahisashi identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT morimotomanabu identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT numatakazushi identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT kagawatatehiro identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT sakamotomichiie identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT kumadatakashi identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment AT maedashin identificationofctvaluesthatcouldbepredictiveofnecrosisnctavinhepatocellularcarcinomaafterlenvatinibtreatment |